267 related articles for article (PubMed ID: 18447603)
1. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis.
Desjeux P
Nat Rev Microbiol; 2004 Sep; 2(9):692. PubMed ID: 15378809
[No Abstract] [Full Text] [Related]
3. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
4. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Rezzano S; Armas JA; Moreno G; Scorza JV
Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
[No Abstract] [Full Text] [Related]
5. Monitoring drug resistance in leishmaniasis.
Croft SL
Trop Med Int Health; 2001 Nov; 6(11):899-905. PubMed ID: 11703844
[TBL] [Abstract][Full Text] [Related]
6. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
7. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
[TBL] [Abstract][Full Text] [Related]
8. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
9. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.
Coser EM; Ferreira BA; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
Acta Trop; 2021 Mar; 215():105806. PubMed ID: 33385363
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis.
Oryan A; Bemani E; Bahrami S
Acta Trop; 2018 Sep; 185():34-41. PubMed ID: 29689189
[TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of leishmaniasis.
Sundar S; Rai M
Curr Opin Infect Dis; 2002 Dec; 15(6):593-8. PubMed ID: 12821836
[TBL] [Abstract][Full Text] [Related]
14. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
[TBL] [Abstract][Full Text] [Related]
15. Clinical status of agents being developed for leishmaniasis.
Berman J
Expert Opin Investig Drugs; 2005 Nov; 14(11):1337-46. PubMed ID: 16255674
[TBL] [Abstract][Full Text] [Related]
16. Paromomycin.
Davidson RN; den Boer M; Ritmeijer K
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):653-60. PubMed ID: 18947845
[TBL] [Abstract][Full Text] [Related]
17. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
18. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
19. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause G; Kroeger A
Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
[No Abstract] [Full Text] [Related]
20. A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis.
Registre C; Soares RDOA; Rubio KTS; Santos ODH; Carneiro SP
ACS Infect Dis; 2023 Mar; 9(3):423-449. PubMed ID: 36795604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
